

**SB 289 A STAFF MEASURE SUMMARY**

**Carrier:** Rep. Munoz

**House Committee On Behavioral Health and Health Care**

---

**Action Date:** 05/06/25

**Action:** Do Pass the A-Eng bill.

**Vote:** 9-0-0-0

**Yeas:** 9 - Diehl, Harbick, Isadore, Javadi, McIntire, Munoz, Nelson, Nosse, Pham H

**Fiscal:** Has minimal fiscal impact

**Revenue:** No revenue impact

**Prepared By:** Brian Nieubuurt, LPRO Analyst

**Meeting Dates:** 4/15, 5/6

---

**WHAT THE MEASURE DOES:**

The measure allows Oregon's Prescription Drug Affordability Board (PDAB) to report annually instead of quarterly and to identify fewer than the nine drugs currently required for affordability review.

Detailed summary:

- Changes the requirement for the Department of Consumer and Business Services (DCBS) to produce a list of drugs exceeding certain price thresholds from each quarter to each year.
- Allows DCBS to identify up to nine drugs (instead of exactly nine) that may create affordability challenges.
- Directs the PDAB to report on the status of the generic drug market in its affordability report to the Health Care Cost Growth Target Program instead of making a separate report to the Legislative Assembly.

**ISSUES DISCUSSED:**

- Colorado review process

**EFFECT OF AMENDMENT:**

No amendment.

**BACKGROUND:**

Oregon's Prescription Drug Affordability Board (PDAB) was established within the Department of Consumer and Business Services (DCBS) by Senate Bill 844 (2021). In its [2024 Annual Report](#), the PDAB recommended several "cleanup" changes to its reporting requirements (2024 Annual Report at p. 11).

Senate Bill 289 A allows the Prescription Drug Association Board to report annually instead of quarterly, to identify fewer than nine drugs for affordability review, and to include reporting on generic drugs in the affordability review report.